EV Biologics Signs Exclusive Distribution Agreement for South America

TAMPA, FL / ACCESSWIRE / May 15, 2023 / EV Biologics Corp (OTC PINK:YECO), today announced that it has signed an exclusive multi-year agreement with INNOVARE for distribution in South America.

This agreement will facilitate the launch, in South America and the Caribbean, of EV Biologics regenerative health products, which are currently in production by its wholly owned subsidiary, EXCYTE.

INNOVARE has long standing relationships and agreements in place with established medical product companies, which have direct distribution channels throughout South America and the Caribbean. With Joint Ventures already in place, this agreement will provide direct contact with over 11,000 top private-practice physicians and surgeons representing all the medical specialties. INNOVARE will also conduct extensive training modules on these regenerative health products and how they may address patients' multifaceted and multifactorial health issues and support cardiovascular, dermatologic, neurologic, and musculoskeletal health and longevity.

CEO, Daniel Mckinney said: "This is a tremendous step forward in our business development. We are looking forward to the launch and sale of our regenerative health products in Q3, 2023 which have the unique potential to synergistically target multiple factors contributing to the development of disease and injury. Through INNOVARE's exclusive distribution channels, we will quickly and directly improve the lives of millions of patients in South America, alone. With ongoing development across the globe, we hope to expand our impact to people worldwide in an enormously positive way, by supporting health and longevity."

The Company will be seeking agents and sole agents in Asian countries for distribution as well.

As announced on February,17, 2023, the Company successfully generated several mesenchymal stem/stromal cell (MSC) lines for secretome production and further cell line development. We plan to utilize these cell banks for production.

About EV Biologics

EV Biologics (formerly Yulong Eco-Materials Limited) is a Wyoming, USA domiciled Biotechnology Company, developing a range of nanotherapeutics to substantially enhance the intrinsic bioactivity of stem and progenitor cell-derived nanoparticles. The Company is also developing biomanufacturing, bioinformatic and bioengineering innovations to optimize production of nanoparticle therapeutics and biologics. These versatile therapeutic platforms will enable generation of nanotherapeutics targeting a broad range of regenerative medicine and longevity applications. Visit www.evbiologics.com